Dr. Michael Pulsipher, MD
Claim this profileChildren's Hospital Los Angeles
Area of expertise
Acute Lymphoblastic Leukemia
Michael Pulsipher, MD has run 7 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
Leukemia
Michael Pulsipher, MD has run 5 trials for Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Children's Hospital Los Angeles
Children's Hospital Of Los Angeles
Clinical Trials Michael Pulsipher, MD is currently running
T Cell-Depleted Stem Cell Transplant
for Leukemia
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Recruiting
1 award
Phase 2
22 criteria
NGS Monitoring
for Acute Lymphoblastic Leukemia
Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it can be hard to achieve remission again. In patients where CART fails, stem cell transplant (HCT) can be used to prevent relapse and achieve cure. But HCT can cause serious side effects. Better testing is needed to distinguish people who can be cured with CART alone from people who may also need to have HCT. Objective: To see if the use of a series of blood and bone marrow tests at regular intervals can help monitor for B-ALL relapse after CART therapy. Eligibility: People aged 1 to 25 years with B-ALL who have had CART therapy within the past 42 days. They must never have had a blood stem cell transplant; they must also have no measurable blood cancer cells. Design: Participants will visit the clinic every 2 weeks starting 42 days after they receive CART therapy. Each visit will be about the same amount of time as a regular clinic visit. about 8 hours. Participants will have blood drawn for testing on each visit. Bone marrow biopsy/aspirate will be done during 4 of the visits at routine timepoints after CART. A needle will be inserted to draw a sample of tissue from inside the bone in the hip. A small amount of blood and tissue will be tested with ClonoSEQ and to evaluate for normal B-cells side by side with the standard tests. The combined testing may help determine whether participants are eligible for HCT and/or at risk of relapse after CART. Participants will be in the study for 2 years.
Recruiting
1 award
N/A
More about Michael Pulsipher, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Michael Pulsipher, MD has experience with
- Fludarabine
- Cyclophosphamide
- Tacrolimus
- Busulfan
- Methotrexate
- Tisagenlecleucel
Breakdown of trials Michael Pulsipher, MD has run
Acute Lymphoblastic Leukemia
Leukemia
Burkitt Lymphoma
Aplastic Anemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Pulsipher, MD specialize in?
Michael Pulsipher, MD focuses on Acute Lymphoblastic Leukemia and Leukemia. In particular, much of their work with Acute Lymphoblastic Leukemia has involved CD19 positive patients, or patients who are HLA-A positive.
Is Michael Pulsipher, MD currently recruiting for clinical trials?
Yes, Michael Pulsipher, MD is currently recruiting for 5 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Michael Pulsipher, MD has studied deeply?
Yes, Michael Pulsipher, MD has studied treatments such as Fludarabine, Cyclophosphamide, Tacrolimus.
What is the best way to schedule an appointment with Michael Pulsipher, MD?
Apply for one of the trials that Michael Pulsipher, MD is conducting.
What is the office address of Michael Pulsipher, MD?
The office of Michael Pulsipher, MD is located at: Children's Hospital Los Angeles, Los Angeles, California 90027 United States. This is the address for their practice at the Children's Hospital Los Angeles.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.